Related Experiment Video
Updated: Jul 5, 2026
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
House dust mite control measures for asthma
1Rigshospitalet, Dept. 3343, Nordic Cochrane Centre. Blegdamsvej 9, Copenhagen Ø, Denmark, 2100. pcg@cochrane.dk
Editorial Note:
This 2011 review predates current reporting standards and methodological expectations for Cochrane Reviews. It should not be used for clinical decision‐making.
Background:
The major allergen in house dust comes from mites. Chemical, physical and combined methods of reducing mite allergen levels are intended to reduce asthma symptoms in people who are sensitive to house dust mites.
Objectives:
To assess the effects of reducing exposure to house dust mite antigens in the homes of people with mite-sensitive asthma.
Search Strategy:
PubMed and The Cochrane Library (last searches Nov 2007), reference lists.
Selection Criteria:
Randomised trials of mite control measures vs placebo or no treatment in people with asthma known to be sensitive to house dust mites.
Data Collection And Analysis:
Two authors applied the trial inclusion criteria and evaluated the data. Trial authors were contacted to clarify information.
Main Results:
Fifty-four trials (3002 patients) were included. Thirty-six trials assessed physical methods (26 mattress encasings), 10 chemical methods, and 8 a combination of chemical and physical methods. Despite the fact that many trials were of poor quality and would be expected to exaggerate the reported effect, we did not find an effect of the interventions. For the most frequently reported outcome, peak flow in the morning (1565 patients), the standardised mean difference was 0.00 (95% confidence interval (CI) -0.10 to 0.10). There were no statistically significant differences either in number of patients improved (relative risk 1.01, 95% CI 0.80 to 1.27), asthma symptom scores (standardised mean difference -0.04, 95% CI -0.15 to 0.07), or in medication usage (standardised mean difference -0.06, 95% CI -0.18 to 0.07).
Authors' Conclusions:
Chemical and physical methods aimed at reducing exposure to house dust mite allergens cannot be recommended. It is doubtful whether further studies, similar to the ones in our review, are worthwhile. If other types of studies are considered, they should be methodologically rigorous and use other methods than those used so far, with careful monitoring of mite exposure and relevant clinical outcomes.
Insights
Reducing house dust mite allergen exposure through chemical or physical methods does not improve asthma symptoms in sensitive individuals. Further research with rigorous methods is recommended to explore alternative interventions.
Area of Science:
- Allergy and Immunology
- Environmental Health
- Respiratory Medicine
Background:
- House dust mites are a primary allergen triggering asthma in sensitive individuals.
- Interventions aim to reduce mite allergen levels to alleviate asthma symptoms.
Purpose of the Study:
- To evaluate the effectiveness of reducing house dust mite allergen exposure in managing asthma in sensitized patients.
Main Methods:
- Systematic review of 54 randomized controlled trials involving 3002 patients.
- Included trials assessed physical, chemical, or combined mite control measures against placebo or no treatment.
- Data extraction and analysis were performed by two authors, with clarification sought from trial authors.
Main Results:
- No statistically significant improvement in asthma symptoms, peak flow, or medication use was observed with mite allergen reduction methods.
- Analysis of 1565 patients for morning peak flow showed a standardized mean difference of 0.00 (95% CI -0.10 to 0.10).
- No significant differences were found in patient improvement (RR 1.01, 95% CI 0.80 to 1.27) or symptom scores (SMD -0.04, 95% CI -0.15 to 0.07).
Conclusions:
- Current chemical and physical methods for reducing house dust mite allergen exposure are not recommended for asthma management.
- Further research should employ methodologically rigorous designs and novel approaches with careful monitoring of mite exposure and clinical outcomes.
More Related Videos
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Asthma-I: Introduction
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Asthma I: Introduction
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Nursing Management
First, in...